drugset / Trial / NCT06019559

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

NCT06019559

Phase 2 Completed 155 enrolled Kallyope Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.

Timeline

Start
2023-09-15
Primary completion
2024-02-07
Completion
2024-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject K-757 Unknown 120 mg Oral
Subject K-833 Unknown 100 mg Oral

Indications